- The company stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.
- Last week, Outlook Therapeutics announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.
- In December 2025, the FDA issued a Complete Response Letter for ONS-5010 / LYTENAVA, saying it could not approve the treatment in its current form for wet AMD.
Outlook Therapeutics Inc. (OTLK) shares plunged 32% in Tuesday’s pre-market trade after the company announced a proposed public offering of its common stock and accompanying warrants.
Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25. The company said it expects aggregate gross proceeds of $5 million and that the offering is expected to close on Wednesday, March 25, 2026.
Retail sentiment on Stocktwits around Outlook Therapeutics trended in the ‘extremely bearish’ territory, with message volumes at ‘high’ levels at the time of writing.
Why Did Outlook Therapeutics Announce The Offering?
Outlook Therapeutics stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.
Last week, the company announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.
Earlier this month, Outlook Therapeutics provided an update with respect to a meeting with the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application for its treatment of wet age-related macular degeneration (wet AMD).
In December 2025, the company said that the FDA issued a Complete Response Letter for its investigational treatment, ONS-5010 / LYTENAVA (bevacizumab-vikg), stating that it cannot approve the application in its present form for the treatment of wet AMD.
The company said that if the FDA approves it, bevacizumab-vikg has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the regulator for use in ophthalmology.
Bevacizumab-vikg is a lab-made antibody that targets a protein called VEGF, which helps blood vessels grow. By blocking VEGF from binding to its receptors on blood vessel cells, the drug prevents the formation of new blood vessels.
How Did Stocktwits Users React?
Outlook Therapeutics’ proposed offering was criticized by a user on the platform, who called out the company for not giving a roadmap on how it intends to use the money, other than meeting its working capital and general corporate needs.
Another user highlighted the lack of data on the uptake of the investigational treatment from patients.
OTLK stock is down 80% year-to-date and 79% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 16% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 38%.
For updates and corrections, email newsroom[at]stocktwits[dot]com.